Ember’s first decade was a journey. The Southern California startup first hit our (and most people’s) radar as a mag company. The company has attracted quite a bit of press attention for its high-end electronic compressor designed to keep drinks at a consistent temperature. Nichi? for sure. Mostly unnecessary? One can certainly make the case. But it was cool (or warm I guess) enough to garner good early adopter buzz.
If it’s February, the company has listed a surprising pole start. CEO Clay Alexander told TechCrunch about Ember’s plans to use its thermal management technology for non-consumer applications. At the end of the year, it became clear that new efforts will be focused on the cold chain – especially medical transportation. A month later, it unveiled the Ember Cube shipping device.
The company announced today that it will strengthen its efforts at Ember Life Sciences. The independent vertical began life with the investment of Cardinal Health, which was announced late last year. Brian Bejarano will join Cardinal as President and General Manager of Ember Life Sciences.
“Ember Cube is the first of many healthcare technologies developed by our team, and Ember LifeSciences is where our innovations in the healthcare space live,” Alexander said in a statement accompanying today’s news. “With Ember Lifesciences, our goal is to disrupt the healthcare distribution industry and improve the way we transport temperature-sensitive medicines and vaccines around the world.”
The new entity has a pair of new shipping containers in the pipeline that build on Cube’s original technology: an “ultra-low-temperature shipper and a cryogenic shipper.” Both are intended to transport cell and gene therapy products and include the same cloud-based temperature reporting, GPS location tracking and return-to-sender technology seen in the Ember Cube.
Between both vaccine releases and endless supply chain issues, there’s never been a hotter time to start a cold chain company.